Akebia Therapeutics, Inc. · Brief

Next report

8 days

Nov 9 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

1 of 8≥ implied

Nov 7 '24±10.6%▼−6.75%×0.64

Mar 13 '25±14.7%▼−12.44%×0.84

May 8 '25±12.4%▲+6.50%×0.52

Aug 7 '25±30.2%▼−20.48%×0.68

Q3 FY25±20.4%▼−18.14%×0.89

Q1 FY26±27.1%▲+9.09%×0.34

May 7 '26±14.2%▼−20.27%×1.43

Q2 FY26±35.9%▼−26.02%×0.73

quarterimplied−40%0+40%realized×

Q2 FY26±35.9%▼−26.02%×0.73

May '26±14.2%▼−20.27%×1.43

Q1 FY26±27.1%▲+9.09%×0.34

Q3 FY25±20.4%▼−18.14%×0.89

Aug '25±30.2%▼−20.48%×0.68

May '25±12.4%▲+6.50%×0.52

2 older reports

Mar '25±14.7%▼−12.44%×0.84

Nov '24±10.6%▼−6.75%×0.64

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 9 report · est.

Bull2 of 3

21disclosed supplier and customer ties in SEC filingsSEC filings

3tracked funds holding AKBAN-PORT · Aug 31 '26

Bear2 of 3

19managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

6 of 25of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

AKBA report session

No linked exposure.

Oct 26impliedImplied move: ±29.7% into Nov 9 earnings (Oct 26 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.